Skip to content
TrialScanner

NCT00258713

A 36-Week Extension to Protocol ISA04-03

Phase 3CompletedAUPHLead

Registry record

Lead sponsor
Aurinia Pharmaceuticals Inc.
Conditions
Psoriasis
Primary completion
Jul 2006Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT00258713 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT00258713: A 36-Week Extension to... | TrialScanner